{
  "url": "https://www.law.cornell.edu/regulations/new-york/N-Y-Comp-Codes-R--Regs-Tit-8-SS-66.5",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 66.5 - [Effective 8/7/2025] Use of therapeutic pharmaceutical agents",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 66.5 - [Effective 8/7/2025] Use of therapeutic pharmaceutical agents\n\nState Regulations\n(a) Definitions. As used in this section: (1)\n\nTopical therapeutic pharmaceutical\nagents\nshall mean those drugs identified in paragraph (e) of\nsubdivision (1) of section\n7101-a\nof the\n\nEducation Law, which shall be limited to topical application to the surface of\nthe eye for therapeutic purposes. (2)\n\nTopical therapeutic pharmaceutical agents for\nthe treatment of glaucoma and ocular hypertension\nshall mean: (i) those drugs identified in paragraph (f) of subdivision\n(1) of section\n7101-a\nof the\n\nEducation Law. (3)\n\nOral therapeutic pharmaceutical agents solely\nfor the treatment of diseases of the eye and adnexa\nshall mean those\ndrugs identified in paragraph (g) of subdivision (1) of section\n7101-a\nof the\n\nEducation Law. (4)\n\nAcceptable accrediting agency\nshall\nmean an organization accepted by the department as a reliable authority for the\npurpose of accrediting at the postsecondary level, applying its criteria for\ngranting accreditation in a fair, consistent, and nondiscriminatory manner, such as an agency recognized for these purposes by the United States Department\nof Education. (5)\n\nEducation Review Committee\nshall mean\nthat committee appointed by the commissioner in consultation with the\nchancellor of the State University of New York, pursuant to subdivision 9 of\nsection\n7101-a\nof the\n\nEducation Law, whose function is to advise and assist the commissioner in\nevaluating acceptable clinical training. (6)\n\nTemporary Evaluation Committee\nshall\nmean that committee appointed by the commissioner of education to advise the\ncommissioner in the evaluation of optometric use of therapeutic pharmaceutical\nagents, pursuant to section 3 of Chapter 517 of the Laws of 1995. (b) Certification requirements. (1) Topical therapeutic pharmaceutical agents. To receive a\ncertificate issued by the department to use topical therapeutic pharmaceutical\nagents, an optometrist shall be licensed in New York and meet the clinical\ntraining requirements set forth in paragraph (1) of subdivision (c) of this\nsection and the examination requirements set forth in subdivision (d) of this\nsection. After certification, such topical therapeutic pharmaceutical agents\nshall be used in accordance with the provisions of Article 143 of the Education\n\nLaw. (2) Topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension. To receive a certificate issued\nby the department to use topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension, an optometrist shall be licensed\nin New York and certified in the use of topical therapeutic pharmaceutical\nagents, as set forth in paragraph (1) of this subdivision, and meet the\nclinical training requirements set forth in paragraph (2) of subdivision (c) of\nthis section and the examination requirements set forth in subdivision (d) of\nthis section. After certification, such topical therapeutic pharmaceutical\nagents for the treatment of glaucoma and ocular hypertension shall be used in\naccordance with the provisions of Article 143 of the Education Law. (3) Oral therapeutic pharmaceutical agents solely for the\ntreatment of diseases of the eye and adnexa. To receive a certificate issued by\nthe Department to use oral therapeutic pharmaceutical agents, an optometrist\nshall be licensed in New York and certified in the use of diagnostic drugs as\nset forth in subdivision (b) of section\n66.4\nof this part, topical\ntherapeutic pharmaceutical agents as set forth in paragraph (1) of this\nsubdivision, and topical therapeutic pharmaceutical agents for the treatment of\nglaucoma and ocular hypertension as set forth in paragraph (2) of this\nsubdivision, and meet the certification course requirements set forth in\nparagraph (3) of subdivision (c) of this section and the examination\nrequirements set forth in subdivision (d) of this section. After certification, such oral therapeutic pharmaceutical agents shall be used in accordance with\nthe provisions of Article 143 of the Education Law. (c) Clinical training and course requirements for\ncertification. (1) To meet the clinical training requirements for\ncertification in the use of topical therapeutic pharmaceutical agents, the\napplicant shall present satisfactory evidence of any of the following: (i) graduation after January 1, 1993 from a professional\nprogram of study in optometry that is registered by the department pursuant to\n\nPart 52 of this Title, or is accredited by an acceptable accrediting agency, or\ndetermined by the department to be the equivalent of such a registered or\naccredited program; or\n(ii) graduation on or before January 1, 1993 from a\nprofessional program of study in optometry that is registered by the department\npursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program; and completion of at least 300 hours\nof acceptable clinical training, as prescribed in subdivision 4(a) and 9-a of\nsection\n7101-a\nof the\n\nEducation Law; or\n(iii) certification to use topical therapeutic\npharmaceutical agents in another jurisdiction, provided that such optometrist\nhas been certified for at least five years to use topical therapeutic\npharmaceutical agents in another jurisdiction during which time such use was\ndemonstrated in independently managed patients, meaning that the optometrist\ndemonstrated that he or she has treated patients with topical therapeutic\npharmaceutical agents without consultation with a licensed physician. (2) To meet the clinical training requirements for\ncertification in the use of topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension, the applicant shall present\nsatisfactory evidence of any of the following: (i) Graduation after January 1, 1993 from a professional\nprogram of study in optometry that is registered by the department pursuant to\n\nPart 52 of this Title, or is accredited by an acceptable accrediting agency, or\ndetermined by the department to be the equivalent of such a registered or\naccredited program; or\n(ii) Graduation on or before January 1, 1993 from a\nprofessional program of study in optometry that is registered by the department\npursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program and completion of at least an\nadditional 100 hours over that obtained for certification to use topical\ntherapeutic pharmaceutical agents of acceptable clinical training, as\nprescribed in subdivisions 4(b) and 9-a of section\n7101-a\nof the\n\nEducation Law; or\n(iii) Certification to use topical therapeutic\npharmaceutical agents for the treatment of glaucoma and ocular hypertension in\nanother jurisdiction, provided that such optometrist has been certified for at\nleast five years to use topical therapeutic agents for the treatment of\nglaucoma and ocular hypertension in another jurisdiction during which time such\nuse was demonstrated in independently managed patients, meaning that the\noptometrist demonstrated that he or she has treated patients with topical\ntherapeutic pharmaceutical agents for the treatment of glaucoma and ocular\nhypertension without consultation with a licensed physician. (3) To meet the course requirements for certification in\nthe use of oral therapeutic pharmaceutical agents, the applicant shall present\nsatisfactory evidence of either: (i) graduation after January 1, 2022 from a professional\nprogram of study in optometry that is registered by the department pursuant to\npart 52 of this Title, or is accredited by an acceptable accrediting agency, or\ndetermined by the department to be the equivalent of such a registered or\naccredited program, and that the applicant has taken and successfully passed\nthe National Board of Examiners in Optometry examination or an examination\nacceptable to the Department; or\n(ii) graduation on or before January 1, 2022 from a\nprofessional program of study in optometry that is registered by the department\npursuant to Part 52 of this Title, or is accredited by an acceptable\naccrediting agency, or determined by the department to be the equivalent of\nsuch a registered or accredited program, and that the applicant has completed a\ncourse of at least 40 hours, as prescribed in paragraph (c) of subdivision 4 of\nsection\n7101-a\nof the\n\nEducation Law. (4) Applicants who meet the clinical training requirements\nfor certification by complying with the requirements of subparagraph (ii) of\nparagraph (1) or subparagraph (ii) of paragraph (2) of this subdivision shall\nsubmit a written application to the department in a form approved by the\ndepartment. The department shall submit each application to the education\nreview committee for its review and recommendation, as prescribed in\nsubdivisions 9 and 9-a of section\n7101-a\nof the\n\nEducation Law. (d) Examination. (1) To meet the examination requirement for either\ncertification in the use of topical therapeutic pharmaceutical agents or\ncertification in the use of topical therapeutic pharmaceutical agents for the\ntreatment of glaucoma and ocular hypertension, the applicant shall present\nevidence of passing of: (a) the treatment and management of ocular diseases portion\nof the examination of the National Board of Examiners in Optometry; or\n(b) an examination determined by the State Board for\n\nOptometry to be equivalent in scope and content to the ocular diseases portion\nof the examination of the National Board of Examiners in Optometry. (2) To meet the examination requirement for certification\nin the use of oral therapeutic pharmaceutical agents, the applicant shall\npresent evidence of passing an examination as prescribed in paragraph (c) of\nsubdivision 4 of section\n7101-a\nof the\n\nEducation Law, and which is acceptable to the Department. Provided, however, that pursuant to subparagraph (v) of paragraph (c) of subdivision 4 of section\n7101-a\nof the\n\nEducation Law, such examination requirement shall not apply to applicants who\nmeet the course requirements prescribed in subparagraph (i) or paragraph (3) of\nsubdivision (c) of this section. (e) Reporting requirement. An optometrist\ncertified to use topical therapeutic pharmaceutical agents for the treatment of\nglaucoma and ocular hypertension shall file with the temporary evaluation\ncommittee a report for each patient treated with topical therapeutic\npharmaceutical agents for the treatment of glaucoma and ocular hypertension\nwithin seven days following the initial and each subsequent visit by the same\npatient. The report shall be in a form developed by the temporary evaluation\ncommittee and approved by the commissioner. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\nยง\n66.5\n\nAmended\n\nNew\n\nYork State Register June 29, 2022/Volume XLIV, Issue 26, eff. 6/29/2022\n\nAmended\n\nNew\n\nYork State Register February 28, 2024/Volume XLVI, Issue 9, eff. 2/28/2024\n\nAmended\n\nNew\n\nYork State Register June 25, 2025/Volume XLVII, Issue 25, eff. 6/9/2025, exp. 8/7/2025\n(Emergency)\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "unknown",
  "source_index": 20248
}